Showing results (81-90 of 160) with videos related to

Sort By:
Pageof 16
Pharmaceutical Research|November 25, 2020
Physiologically Based Pharmacokinetic Models of Probenecid and Furosemide to Predict Transporter Mediated Drug-Drug InteractionsHannah Britz, Nina Hanke, Mitchell E Taub, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|February 21, 2003
Pharmacokinetics and bioavailability of denaverine hydrochloride in healthy subjects following intravenous, oral and rectal single dosesAlexander Staab, Barbara S Schug, Véronique Larsimont, et al.
CPT: Pharmacometrics & Systems Pharmacology|February 15, 2019
Physiologically-Based Pharmacokinetic Models for CYP1A2 Drug-Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and MidazolamHannah Britz, Nina Hanke, Anke-Katrin Volz, et al.
Pharmaceutics|October 27, 2022
Pharmacometric Modeling of the Impact of Azelastine Nasal Spray on SARS-CoV-2 Viral Load and Related Symptoms in COVID-19 PatientsChristiane Dings, Peter Meiser, Frank Holzer, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|October 24, 2024
Burden of cardiovascular disease attributable to metabolic risks in 204 countries and territories from 1990 to 2021Huimin Chen, Lu Liu, Yi Wang, et al.
Cancer Chemotherapy and Pharmacology|January 12, 2010
Semi-mechanistic population pharmacokinetic/pharmacodynamic model for neutropenia following therapy with the Plk-1 inhibitor BI 2536 and its application in clinical developmentElena Soto, Alexander Staab, Christiane Tillmann, et al.
Clinical Pharmacokinetics|February 1, 2015
Population Pharmacokinetics and Pharmacodynamics of Linagliptin in Patients with Type 2 Diabetes MellitusSilke Retlich, Vincent Duval, Ulrike Graefe-Mody, et al.
CPT: Pharmacometrics & Systems Pharmacology|June 17, 2025
Development and Verification of a Physiologically Based Pharmacokinetic Model of Furmonertinib and Its Main Metabolite for Drug-Drug Interaction PredictionsYali Wu, Helena Leonie Hanae Loer, Yifan Zhang, et al.
The Lancet Regional Health. Europe|December 11, 2023
Efficacy and safety of MP1032 plus standard-of-care compared to standard-of-care in hospitalised patients with COVID-19: a multicentre, randomised double-blind, placebo-controlled phase 2a trialPetra Sager, Astrid Kaiser, Sara Schumann, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 2, 2024
A physiologically-based pharmacokinetic precision dosing approach to manage dasatinib drug-drug interactionsChristina Kovar, Helena Leonie Hanae Loer, Simeon Rüdesheim, et al.
Pageof 16